Catalyst Pharmaceuticals, Inc. CPRX R2K
Healthcare · Biotechnology · United States
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
READ MORE ›$31.23
+25.12% 1Y
Market & Price
Market Cap
$3.82B
Current Price
$31.23
High / Low (52W)
$31.33 / $19.13
Beta
0.72
Valuation
Stock P/E
18.05
Industry PE
23.65
Forward P/E
9.96
PEG Ratio
-
Book Value
$8.29
Price to Book
3.77
P/S
6.40
EV/EBITDA
10.03
Dividend Yield
-
Profitability & Returns
ROCE
26.94%
ROE
24.50%
ROA
16.27%
Profit Margin
37.08%
Op Margin
49.02%
EPS (Latest Qtr)
$0.50
EPS (TTM)
$1.73
Balance Sheet & Liquidity
Debt/Equity
0.27
Quick Ratio
6.70
Current Ratio
7.10
Debt
$2.68M
Total Assets
$1.10B
Current Assets
$894.03M
Working Capital
$746.88M
Ownership
Promoter Holding
5.57%
Chg in Prom Hold
-
FII / Inst Holding
89.34%
Chg in FII Hold
0.00%
Financial Snapshot
Enterprise Value
$3.07B
Total Revenue (TTM)
$596.96M
EBITDA
$305.83M
Free Cash Flow
$171.81M
Operating Cash Flow
$208.21M
Shares Outstanding
122.38M
Gross Margin
84.04%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
40.10%
Profit 5Y
37.15%
Revenue (YoY)
5.60%
Earnings (YoY)
11.10%
PROS
- Strong return on equity of 24.5%.
- Healthy ROCE of 26.9%.
- Excellent profit margin of 37.1%.
- Compounding revenue at 40.1% over 5 years.
- Profit CAGR of 37.1% over 5 years.
- Generates positive free cash flow.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CPRX Catalyst Pharmaceuticals, Inc. R2K | 31.23 | 18.05 | $3.82B | - | 26.94% | 24.50% | 40.10% | 37.15% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.45M | 28.84M | 30.90M | 30.12M | 29.14M | 29.61M | 29.32M | 30.20M | 36.37M | 35.95M | 43.09M | 53.11M | 57.24M | 85.37M | 99.58M | 102.69M | 98.51M | 122.71M | - | - | 141.42M | 146.56M | 148.39M | 152.61M | 149.39M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.91M | 20.61M | 22.65M | 26.07M | 14.47M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 123.51M | 125.95M | 125.74M | 126.54M | 134.91M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 60.14M | 59.65M | 59.47M | 64.69M | 61.68M |
| Operating Income | -4.90M | -5.02M | -6.19M | -6.24M | -4.81M | -3.91M | -4.31M | -4.68M | -4.18M | -4.31M | -5.51M | -5.93M | -6.34M | -8.18M | -14.84M | -987.77K | 10.96M | 13.85M | 8.01M | 10.70M | 10.28M | 11.70M | 9.80M | 15.84M | 14.00M | 17.37M | 28.57M | 25.10M | 35.61M | 46.70M | -37.19M | 27.13M | 54.25M | - | - | 63.37M | 66.30M | 66.27M | 61.85M | 73.23M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 72.83M | 75.76M | 75.68M | 71.38M | 83.00M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 71.29M | 69.29M | 71.03M | 71.90M | 84.23M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.55M | 17.18M | 18.25M | 19.20M | 20.50M |
| Net Income | -4.56M | -4.45M | -5.82M | -5.39M | -4.57M | -3.95M | -4.16M | -4.97M | -3.88M | -4.18M | -5.39M | -5.70M | -5.97M | -7.84M | -14.50M | -644.50K | 10.96M | 13.63M | 7.93M | 10.43M | 9.78M | 43.34M | 7.66M | 12.18M | 10.33M | 13.24M | 21.62M | 22.75M | 29.57M | 37.76M | -30.76M | 23.27M | 40.79M | - | - | 56.74M | 52.11M | 52.78M | 52.70M | 63.73M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.06 | -0.08 | - | -0.01 | 0.10 | 0.13 | 0.07 | 0.10 | 0.09 | 0.41 | 0.07 | 0.11 | 0.10 | 0.12 | 0.20 | 0.20 | 0.26 | 0.33 | -0.29 | 0.19 | 0.33 | - | - | 0.45 | 0.41 | 0.42 | 0.41 | 0.50 |
| R&D Expense | 2.58M | 3.04M | - | 3.55M | 2.51M | 2.49M | - | 2.81M | 2.45M | 2.70M | - | 3.26M | 3.70M | 4.54M | - | 3.31M | 4.63M | 4.60M | - | 4.22M | 4.35M | 3.75M | 3.01M | 4.45M | 4.49M | 3.40M | 3.98M | 8.31M | 3.56M | 3.95M | 83.66M | 2.58M | 2.98M | 3.28M | - | 3.89M | 4.36M | 2.66M | - | 2.66M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 102.31M | 119.07M | - | 214.20M | 398.20M | 491.73M | 588.99M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.39M | 51.97M | 68.84M | 87.25M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 179.81M | 346.24M | 422.89M | 501.74M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 77.97M | 259.43M | 227.76M | 243.96M |
| Operating Income | - | - | - | - | - | - | - | -7.28M | -4.02M | -6.08M | -5.22M | -10.31M | -14.59M | -20.40M | -19.28M | -18.68M | -35.30M | 31.82M | 41.30M | - | 101.84M | 86.81M | 195.12M | 257.78M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 103.08M | 119.69M | 232.90M | 295.65M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 104.72M | 94.51M | 216.26M | 283.51M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.64M | 23.10M | 52.37M | 69.19M |
| Net Income | -255.94K | -428.62K | -539.82K | -1.81M | -2.73M | -4.14M | -10.56M | -7.24M | -4.01M | -6.39M | -4.08M | -12.15M | -15.51M | -20.23M | -18.07M | -18.41M | -34.00M | 31.88M | 74.98M | - | 83.08M | 71.41M | 163.89M | 214.33M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.33 | 0.30 | 0.71 | - | 0.75 | 0.63 | 1.31 | 1.68 |
| R&D Expense | - | - | - | - | - | - | - | 5.10M | 2.31M | 3.38M | 2.66M | 8.10M | 10.12M | 11.80M | 11.37M | 11.38M | 19.92M | 18.84M | 16.50M | 16.94M | 19.79M | 93.15M | 12.65M | 12.71M |
Compounded Sales Growth
| 5 Years: | 40.10% |
| 1 Year: | 5.60% |
Compounded Profit Growth
| 5 Years: | 37.15% |
| 1 Year: | 11.10% |
Stock Price Performance
| 1 Year: | +25.12% |
| 6 Months: | +32.39% |
| 3 Months: | +35.31% |
| 1 Month: | +10.51% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2002 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | - | - | 5.83M | 6.25M | 16.79M | 25.37M | 43.91M | 60.10M | 41.71M | 85.39M | 60.45M | 112.38M | 192.35M | - | 375.63M | 470.11M | 851.41M | 1.10B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 320.81M | 219.33M | 623.61M | 894.03M |
| Cash & Equivalents | 100.00K | - | - | - | - | - | - | 11.77M | 7.78M | 5.48M | 6.03M | 1.41M | 2.22M | 9.10M | 28.24M | 13.89M | 57.50M | 16.56M | 89.51M | 130.24M | - | 298.39M | 137.64M | 517.55M | 709.17M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.80M | 15.64M | 19.54M | 37.17M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.44M | 53.51M | 65.48M | 126.48M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | 313.71K | 2.49M | 2.17M | 3.98M | 8.67M | 4.63M | 2.40M | 4.42M | 9.67M | 24.75M | 22.76M | - | 75.21M | 82.23M | 123.78M | 149.71M |
| Current Liabilities | - | - | - | - | - | - | - | - | - | 298.96K | 833.80K | 1.65M | 2.14M | 5.86M | 3.44M | 2.09M | 4.27M | 9.51M | 24.10M | 22.76M | - | 57.59M | 76.06M | 120.68M | 147.15M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.89M | 3.56M | 3.19M | 2.79M |
| Total Equity | 100.00K | 44.89K | 362.56K | 117.58K | 446.46K | 19.85M | 16.32M | 10.56M | 7.62M | 5.52M | 3.76M | 14.62M | 21.39M | 35.24M | 55.48M | 39.31M | 80.96M | 50.78M | 87.63M | 169.60M | - | 300.42M | 387.88M | 727.63M | 954.27M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 105.26M | 107.12M | 120.88M | 122.51M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.68M | -3.76M | -4.99M | -5.14M | -9.88M | - | - | - | -13.74M | -26.15M | 34.61M | 45.03M | - | 116.05M | 143.60M | 239.81M | 208.67M |
| Investing Cash Flow | -2.30K | -2.87K | -3.62K | -14.06M | -7.50M | - | - | - | -3.96K | -15.08M | 37.23M | -5.01M | - | 9.21M | -293.50M | -556.00K | -58.00K |
| Financing Cash Flow | 3.70M | 1.46M | 5.54M | 14.58M | 18.18M | - | - | - | 57.35M | 293.12K | 1.12M | 702.00K | - | 1.69M | -10.86M | 140.66M | -16.99M |
| Capital Expenditure | -2.30K | -2.87K | -3.62K | -52.38K | -9.43K | -57.32K | -23.46K | -96.06K | - | -92.02K | -19.00K | -11.00K | - | -29.00K | -81.74M | -556.00K | -58.00K |
| Free Cash Flow | -7.69M | -3.76M | -4.99M | -5.19M | -9.89M | - | - | - | - | -26.24M | 34.59M | 45.02M | - | 116.02M | 61.86M | 239.25M | 208.61M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | 126.95M | -160.76M | 379.92M | 191.62M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | 12.09M | 6.91M | 0 | 0 | 25.30M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 83.9% | 86.9% | 86.0% | 85.2% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 31.1% | 34.7% | - | 47.5% | 21.8% | 39.7% | 43.8% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 31.2% | 63.0% | - | 38.8% | 17.9% | 33.3% | 36.4% |
| ROE % | -570.2% | -118.2% | -459.1% | -404.4% | -13.8% | -25.4% | -100.0% | -95.1% | -72.6% | -169.9% | -27.9% | -56.8% | -44.0% | -36.5% | -46.0% | -22.7% | -67.0% | 36.4% | 44.2% | - | 27.7% | 18.4% | 22.5% | 22.5% |
| ROCE % | - | - | - | - | - | - | - | - | -72.7% | -112.3% | -34.5% | -44.4% | -38.3% | -36.0% | -48.7% | -23.0% | -69.3% | 36.0% | 24.4% | - | 32.0% | 22.0% | 26.7% | 26.9% |
Shareholding Pattern
Insiders
5.57%
Institutions
89.34%
Public Float
94.61%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.34% | 18.77M | $586.33M |
| 2 | State Street Corporation | 5.61% | 6.86M | $214.33M |
| 3 | Vanguard Capital Management LLC | 4.19% | 5.12M | $159.98M |
| 4 | American Century Companies Inc | 3.38% | 4.14M | $129.24M |
| 5 | Deerfield Management Company, L.P | 3.22% | 3.94M | $123.16M |
| 6 | Dimensional Fund Advisors LP | 2.80% | 3.43M | $107.11M |
| 7 | Bank of America Corporation | 2.48% | 3.04M | $94.83M |
| 8 | Geode Capital Management, LLC | 2.43% | 2.97M | $92.83M |
| 9 | Morgan Stanley | 2.20% | 2.69M | $83.92M |
| 10 | Vanguard Portfolio Management LLC | 2.02% | 2.48M | $77.31M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CPRX
No recent headlines available.